Home
Valuation

Work Area: Valuation

South Korea’s IP-backed lending market growth exceeds targets

Although heavy reliance on government-backed initiatives creates uncertain future for IP holders

‘Live or die’: LG Chem prepares to launch series of disputes as strategy pivots, reveals IP head

The Korean chemicals giant will do anything to combat “harsh competition” and IP is one of the “crucial” tools for securing success, contends IP head Kyung-Hwa Min

JS Held expands Ocean Tomo IP practice with new acquisition

The global scientific and engineering consultancy has bought TechPats, a patent-focused technical expert firm, at a time when an uncertain economy and declining number of M&As has led some companies to issue layoff notices to IP staff

Latest content

Key takeaways from Merck’s landmark covid IP licensing deal with the Medicines Patent Pool

The agreement is the first granting non-exclusive and royalty free rights to sub-licensees of a covid therapeutic or vaccine

02 November 2021

Flexibility crucial to growing appeal of big money drug royalty transactions, says leading deal-maker

In the wake of the firm’s latest $250 million investment, Sagard Healthcare Royalty Partners’ Ali Alagheband gives the inside track on life sciences IP-backed revenue sales

01 November 2021

Nokia Technologies boosts revenues and profits in strong Q3 patent licensing performance

Royalties grow on the back of new deals and renewals; company also shares new details on legal fight with Oppo, which does not appear to have significantly dimmed income outlook

29 October 2021

Hub and spoke IP strategies are generating billions of dollars in biopharma

New Crinetics spin-off is more evidence of the growing influence of models designed to monetise non-core life sciences assets

22 October 2021

Investment in medical device IP is surging

Diagnostic innovation buyouts drive resurgence of med-tech deal-making

19 October 2021

Ericsson turns in strong licensing quarter with Apple renewal looming

Continued impact of Samsung deal pushes Swedish company’s royalty take near $300 million – but executives warn upcoming re-negotiations could produce temporary disruption again

19 October 2021

Four IP takeaways from Merck’s $11.5 billion Acceleron acquisition

Merck has struck the biggest life sciences M&A deal of 2021 so far. Here are the four key IP-related takeaways.

07 October 2021

Amgen’s Otezla win vindicates multi-billion-dollar IP purchase

US federal court victory sets up the $13.4 billion drug for exclusivity until 2028

05 October 2021

Purchase of Alphabet rights marks rare patent acquisition for Japan’s Softbank

Assignment records show that despite parent company’s vast backing for startups, Softbank Corp and its affiliates have not often come into the possession of significant third-party portfolios

04 October 2021

What patent owners need to know about financing life sciences disputes

The Long Read: Companies in the life sciences sector have increasing options when seeking outside investment in IP enforcement campaigns, writes Michael Gulliford. But unique legal considerations and risk factors call for careful structuring of deals

29 September 2021

Unlock unlimited access to all IAM content